65,437 trials
Physical Activity
Primary: Total Physical Activity — 34.21; 37.80; 39.42 total metabolic equivalent
Pediatric Patients With Acute Lymphoblastic Leukemia
Primary: Local Reactions After Each Vaccination — 12; 7; 14; 9 Participants
Entropion
Primary: Extubation Time — 756.3; 425.9 seconds
Hemophilia A · Hemophilia B
Primary: Age of Participants at Disease Diagnosis — 5; 7 years
Healthy
Primary: Peak Plasma Concentration (Cmax) of ASP2151 — 1818.0; 1202.3; 3573.1; 2452.1 ng/mL
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants
Prediabetes
Primary: Vascular Endothelial Function — -307; -34.8; -36.8; -110 %*min
Neuropathic Pain
Primary: Percentage of Participants With Adverse Drug Reaction — 12.75 Percentage of Participants
Sepsis
Primary: All-cause Neonatal Mortality — 282; 263; 18168; 19045 participants
Ocular Hypertension · Glaucoma, Open-Angle
Primary: Mean Intraocular Pressure — 14.7; 14.8 mmHg
Asthma
Primary: Clinical Asthma Exacerbation (CAE) Rate: Percentage of Participants Who Experienced at Least 1 Moderate or Severe CAE — 17 percentage of participants
Parkinson's Disease
Primary: Step Length During Gait — 0.57; 0.63; 0.54; 0.72 meters
Cervical Ripening · Induction of Labor
Primary: The Median Times From Placement of Foley Catheter to Vaginal Delivery — 21.2; 31.3; 17.1; 14.8 hours
Adhesion
Primary: Number of Participants With Adverse Events (AEs) — 16; 17 Participants
Chronic Pancreatitis
Primary: Malabsorption Blood Test: Difference in Mean HA AUC Between Groups: Subjects With CP Compared to Healthy Subjects — 8.3; 17.7 mg*h/dL — p=<0.001